HomeGOVXW • NASDAQ
add
GeoVax
Nakaraang pagsara
$0.036
Sakop ng taon
$0.014 - $0.65
Market cap
14.46M USD
Average na Volume
14.24K
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.64M | — |
Gastos sa pagpapatakbo | 1.69M | 15.76% |
Net na kita | -5.36M | 8.41% |
Net profit margin | -327.31 | — |
Kita sa bawat share | — | — |
EBITDA | -5.38M | 8.23% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 7.44K | -99.03% |
Kabuuang asset | 10.83K | -99.68% |
Kabuuang sagutin | 2.94K | -99.91% |
Kabuuang equity | 7.90K | — |
Natitirang share | 13.84M | — |
Presyo para makapag-book | ∞ | — |
Return on assets | -330.92% | — |
Return on capital | -534.47% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -5.36M | 8.41% |
Cash mula sa mga operasyon | — | — |
Cash mula sa pag-invest | — | — |
Cash mula sa financing | — | — |
Net change in cash | — | — |
Malayang cash flow | — | — |
Tungkol
GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. Wikipedia
Itinatag
1988
Headquarters
Website
Mga Empleyado
17
